Adaptive Biotechnologies Overview
- Year Founded
-
2009
- Status
-
Public
- Employees
-
624
- Stock Symbol
-
ADPT
- Investments
-
1
- Share Price
-
$29.05
- (As of Friday Closing)
Adaptive Biotechnologies General Information
Description
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
Contact Information
Website
www.adaptivebiotech.comCorporate Office
- 1165 Eastlake Avenue East
- Seattle, WA 98109
- United States
Corporate Office
- 1165 Eastlake Avenue East
- Seattle, WA 98109
- United States
Adaptive Biotechnologies Stock Performance
As of 13-Nov-2026, Adaptive Biotechnologies’s stock price is $29.05. Its current market cap is $4.7B with 162M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $29.05 | $29.48 | $12.00 - $32.21 | $4.7B | 162M | 2.18M | -$0.45 |
Adaptive Biotechnologies Financials Summary
As of 30-Sep-2026, Adaptive Biotechnologies has a trailing 12-month revenue of $298M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 4,686,312 | 2,348,135 | 733,036 | 439,465 |
| Revenue | 298,010 | 276,976 | 178,957 | 170,276 |
| EBITDA | (56,606) | (39,290) | (143,293) | (204,804) |
| Net Income | (70,524) | (59,499) | (159,492) | (225,250) |
| Total Assets | 683,120 | 512,736 | 539,376 | 661,134 |
| Total Debt | 408,971 | 79,148 | 89,387 | 98,772 |
Adaptive Biotechnologies Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Adaptive Biotechnologies Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Adaptive Biotechnologies Comparisons
Industry
Financing
Details
Adaptive Biotechnologies Competitors (38)
One of Adaptive Biotechnologies’s 38 competitors is Allogene Therapeutics, a Formerly VC-backed company based in South San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Allogene Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA | ||||
| Gelesis | Formerly VC-backed | Calimera, Italy | ||||
| GeneDx Holding | Formerly VC-backed | Stamford, CT | ||||
| Aura Biosciences | Formerly VC-backed | Boston, MA |
Adaptive Biotechnologies Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Adaptive Biotechnologies Patents
Adaptive Biotechnologies Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2025217102-A1 | Multiple sclerosis-associated t cell receptor-related methods and compositions | Pending | 31-Jan-2024 | ||
| WO-2025166071-A1 | Multiple sclerosis-associated t cell receptor-related methods and compositions | Pending | 31-Jan-2024 | ||
| US-20250074966-A1 | Agents and methods for preventing or inhibiting adaptive immune responses associated with multiple sclerosis | Pending | 31-Aug-2023 | ||
| WO-2025050088-A1 | Agents and methods for preventing or inhibiting adaptive immune responses associated with multiple sclerosis | Inactive | 31-Aug-2023 | ||
| AU-2024228388-A1 | Therapeutic t cell receptors targeting kras g12d | Pending | 27-Feb-2023 | A61K39/0011 |
Adaptive Biotechnologies Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Adaptive Biotechnologies Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Adaptive Biotechnologies Acquisitions (1)
Adaptive Biotechnologies’s most recent deal was a Merger/Acquisition with Sequenta. The deal was made on 07-Jan-2015.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Sequenta | 07-Jan-2015 | Merger/Acquisition | Biotechnology |
Adaptive Biotechnologies ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
22.69 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Laboratory Equipment and Services
Subindustry
of 67
Rank
Percentile
Adaptive Biotechnologies FAQs
-
When was Adaptive Biotechnologies founded?
Adaptive Biotechnologies was founded in 2009.
-
Where is Adaptive Biotechnologies headquartered?
Adaptive Biotechnologies is headquartered in Seattle, WA.
-
What is the size of Adaptive Biotechnologies?
Adaptive Biotechnologies has 624 total employees.
-
What industry is Adaptive Biotechnologies in?
Adaptive Biotechnologies’s primary industry is Biotechnology.
-
Is Adaptive Biotechnologies a private or public company?
Adaptive Biotechnologies is a Public company.
-
What is Adaptive Biotechnologies’s stock symbol?
The ticker symbol for Adaptive Biotechnologies is ADPT.
-
What is the current stock price of Adaptive Biotechnologies?
As of 13-Nov-2026 the stock price of Adaptive Biotechnologies is $29.05.
-
What is the current market cap of Adaptive Biotechnologies?
The current market capitalization of Adaptive Biotechnologies is $4.7B.
-
What is Adaptive Biotechnologies’s current revenue?
The trailing twelve month revenue for Adaptive Biotechnologies is $298M.
-
Who are Adaptive Biotechnologies’s competitors?
Allogene Therapeutics, Inovio Pharmaceuticals, Gelesis, GeneDx Holding, and Aura Biosciences are some of the 38 competitors of Adaptive Biotechnologies.
-
What is Adaptive Biotechnologies’s annual earnings per share (EPS)?
Adaptive Biotechnologies’s EPS for 12 months was -$0.45.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
